Homepage > Company > Media > Pharma News > 2017 > Teva intros generic Axiron in the U.S.

Teva intros generic Axiron in the U.S.

JERUSALEM — Teva late last week announced the launch of generic Axiron (testosterone) topical solution CIII, 30-mg-1.5-mL, in the United States.

Testosterone topical solution CIII is a prescription medicine used to treat adult males who have low or no testosterone due to certain medical conditions. It is supplied in a metered dose pump with an underarm applicator.

ChemSpider 2D Image | Testosterone | C19H28O2

Axiron had annual sales of approximately $247 million in the U.S., according to IMS data as of May 2017.

August 22, 2017

http://www.drugstorenews.com/

Read also

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...